<SEC-DOCUMENT>0000080255-25-000848.txt : 20251114
<SEC-HEADER>0000080255-25-000848.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114121923
ACCESSION NUMBER:		0000080255-25-000848
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BridgeBio Pharma, Inc.
		CENTRAL INDEX KEY:			0001743881
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91059
		FILM NUMBER:		251483433

	BUSINESS ADDRESS:	
		STREET 1:		3160 PORTER DR.
		STREET 2:		SUITE 250
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		(650) 391-9740

	MAIL ADDRESS:	
		STREET 1:		3160 PORTER DR.
		STREET 2:		SUITE 250
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BridgeBio Pharma LLC
		DATE OF NAME CHANGE:	20180618

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRICE T ROWE ASSOCIATES INC /MD/
		CENTRAL INDEX KEY:			0000080255
		STANDARD INDUSTRIAL CLASSIFICATION:	SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES [6200]
		ORGANIZATION NAME:           	09 Crypto Assets
		EIN:				520556948
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		1307 POINT STREET
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21231
		BUSINESS PHONE:		(410)345-2000

	MAIL ADDRESS:	
		STREET 1:		P.O. BOX 89000
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21289
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:ns2="http://www.sec.gov/edgar/common">
    <headerData>
        <submissionType>SCHEDULE 13G</submissionType>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0000080255</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>


        </filerInfo>
    </headerData>
    <formData>
        <coverPageHeader>
            <securitiesClassTitle>COMMON STOCK</securitiesClassTitle>
            <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
            <issuerInfo>
                <issuerCik>0001743881</issuerCik>
                <issuerName>BridgeBio Oncology Therapeutics Inc</issuerName>
                <issuerCusip>107924102</issuerCusip>
                <issuerPrincipalExecutiveOfficeAddress>
                    <ns2:street1>3160 PORTER DR.</ns2:street1>
                    <ns2:street2>SUITE 250</ns2:street2>
                    <ns2:city>PALO ALTO</ns2:city>
                    <ns2:stateOrCountry>CA</ns2:stateOrCountry>
                    <ns2:zipCode>94304</ns2:zipCode>
                </issuerPrincipalExecutiveOfficeAddress>
            </issuerInfo>
            <designateRulesPursuantThisScheduleFiled>
                <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
            </designateRulesPursuantThisScheduleFiled>
        </coverPageHeader>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>T. Rowe Price Associates, Inc.</reportingPersonName>
            <citizenshipOrOrganization>MD</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>885042</soleVotingPower>
                <sharedVotingPower>0</sharedVotingPower>
                <soleDispositivePower>885042</soleDispositivePower>
                <sharedDispositivePower>0</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>885042</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
            <classPercent>1.1</classPercent>
            <typeOfReportingPerson>IA</typeOfReportingPerson>
        </coverPageHeaderReportingPersonDetails>
        <items>
            <item1>
                <issuerName>BridgeBio Oncology Therapeutics Inc</issuerName>
                <issuerPrincipalExecutiveOfficeAddress>3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304</issuerPrincipalExecutiveOfficeAddress>
            </item1>
            <item2>
                <filingPersonName>T. Rowe Price Associates, Inc.</filingPersonName>
                <principalBusinessOfficeOrResidenceAddress>1307 Point Street, Baltimore, MD 21231</principalBusinessOfficeOrResidenceAddress>
                <citizenship>Maryland</citizenship>
            </item2>
            <item3>
                <notApplicableFlag>N</notApplicableFlag>
                <typeOfPersonFiling>IA</typeOfPersonFiling>
            </item3>
            <item4>
                <amountBeneficiallyOwned>885042</amountBeneficiallyOwned>
                <classPercent>1.1</classPercent>
                <numberOfSharesPersonHas>
                    <solePowerOrDirectToVote>885042</solePowerOrDirectToVote>
                    <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
                    <solePowerOrDirectToDispose>885042</solePowerOrDirectToDispose>
                    <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
                </numberOfSharesPersonHas>
            </item4>
            <item5>
                <notApplicableFlag>N</notApplicableFlag>
                <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
            </item5>
            <item6>
                <notApplicableFlag>Y</notApplicableFlag>
            </item6>
            <item7>
                <notApplicableFlag>Y</notApplicableFlag>
            </item7>
            <item8>
                <notApplicableFlag>Y</notApplicableFlag>
            </item8>
            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
            </item9>
            <item10>
                <notApplicableFlag>N</notApplicableFlag>
                <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.</certifications>
            </item10>
        </items>
        <signatureInformation>
            <reportingPersonName>T. Rowe Price Associates, Inc.</reportingPersonName>
            <signatureDetails>
                <signature>Ellen York</signature>
                <title>Vice President</title>
                <date>11/14/2025</date>
            </signatureDetails>
        </signatureInformation>
    </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
